Genetic Alterations in Differentiated Thyroid Cancers

Author(s): Behrouz Salehian, Zhong Liu, Fouad Kandeel

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders

Volume 9 , Issue 3 , 2009

Become EABM
Become Reviewer
Call for Editor


Differentiated thyroid cancers are the predominant malignancies of the thyroid. Due to advances in the understanding of the activation of the cell proliferation pathway at a molecular level, multiple genetic alterations have been linked to the development of thyroid carcinogenesis. Although the genetic alterations can be categorized into 7 categories, the BRAF mutation, RET/PTC, Pax8/PPARGamma, and dysfunctional Fas pathway have been most commonly described. Each of the gene alterations can ultimately result in cancer development, invasion and/or metastasis. This article provides a detailed review of the altered cell proliferation pathway activations found in thyroid carcinogenesis. The molecular targets that may be disrupted by therapeutic agents during the abnormal proliferation are also summarized.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [257 - 268]
Pages: 12
DOI: 10.2174/187153009789044338
Price: $65

Article Metrics

PDF: 10